Journal of Clinical Oncology, Vol 21, Issue 7
(April), 2003: 1285-1292
© 2003 American Society for Clinical Oncology
Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer
Michael P. Mac Manus,
Rodney J. Hicks,
Jane P. Matthews,
Allan McKenzie,
Danny Rischin,
Eeva K. Salminen,
David L. Ball
1 From the Department of Radiation Oncology, Department of Diagnostic Imaging, Statistical Centre and Department of Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia, and the University of Turku, Turku, Finland.
Address reprint requests to Michael Mac Manus, MD, Department of Radiation Oncology, Peter MacCallum Cancer Institute, St Andrew’s Place, East Melbourne, Victoria 3000, Australia; email: mmanus{at}petermac.unimelb.edu.au.
Purpose: To prospectively study the capacity of positron emission tomography (PET) and computed tomography (CT) to determine response soon after radical radiotherapy or chemoradiotherapy and, thereby, predict survival. PET is known to provide a more accurate estimate of true extent of disease than CT when used to stage non–small-cell lung cancer (NSCLC).
Patients and Methods: Seventy-three patients with NSCLC underwent [18F]fluorodeoxyglucose PET and CT scans before and after radical radiotherapy (n = 10) or chemoradiotherapy (n = 63). Follow-up PET scans were performed at a median of 70 days after radiotherapy. The median PET-CT interval was 1 day. Each patient had determinations of response to therapy made with PET and CT, categorized as complete response, partial response, no response, progressive disease, or nonassessable. Responses were correlated with subsequent survival.
Results: Median survival after follow-up PET was 24 months. There was poor agreement between PET and CT responses (weighted kappa = 0.35), which were identical in only 40% of patients. There were significantly more complete responders on PET (n = 34) than CT (n = 10), whereas fewer patients were judged to be nonresponders (12 patients on PET v 20 on CT) or nonassessable (zero patients on PET v six on CT) by PET. Both CT and PET responses were individually significantly associated with survival duration; but on multifactor analysis that included the known prognostic factors of CT response, performance status, weight loss, and stage, only PET response was significantly associated with survival duration (P < .0001).
Conclusion: In NSCLC, a single, early, posttreatment PET scan is a better predictor of survival than CT response, stage, or pretreatment performance status.
Presented in part at the Forty-Third Annual Meeting of the American Society for Therapeutic Radiology and Oncology, San Francisco, CA, November 6–8, 2001, and the Thirty-Sixth Annual Meeting American Society for Clinical Oncology in New Orleans, LA, May 19–23, 2000.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
122S - 150S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Hicks
Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
31S - 42S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Erasmus, E. Rohren, and S. G. Swisher
Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging
Proceedings of the ATS,
April 15, 2009;
6(2):
171 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Allen-Auerbach and W. A. Weber
Measuring Response with FDG-PET: Methodological Aspects
Oncologist,
April 1, 2009;
14(4):
369 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al.
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose
J. Clin. Oncol.,
February 1, 2009;
27(4):
535 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Zhao, L. H. Schwartz, and S. M. Larson
Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers
J. Nucl. Med.,
February 1, 2009;
50(2):
239 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. Weber
The Use of Positron Emission Tomography versus Computerized Tomography Scans in the Assessment of Response to Therapy
ASCO Educational Book,
January 1, 2009;
2009(1):
474 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tanvetyanon, E. A. Eikman, E. Sommers, L. Robinson, D. Boulware, and G. Bepler
Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
October 1, 2008;
26(28):
4610 - 4616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Dunnwald, J. R. Gralow, G. K. Ellis, R. B. Livingston, H. M. Linden, J. M. Specht, R. K. Doot, T. J. Lawton, W. E. Barlow, B. F. Kurland, et al.
Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
J. Clin. Oncol.,
September 20, 2008;
26(27):
4449 - 4457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. P. Worden, B. Kumar, J. S. Lee, G. T. Wolf, K. G. Cordell, J. M.G. Taylor, S. G. Urba, A. Eisbruch, T. N. Teknos, D. B. Chepeha, et al.
Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number
J. Clin. Oncol.,
July 1, 2008;
26(19):
3138 - 3146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. Toner and R. J. Hicks
PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
Oncologist,
April 1, 2008;
13(suppl_2):
22 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA,
November 21, 2007;
298(19):
2289 - 2295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology,
November 1, 2007;
245(2):
333 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.-F. de Geus-Oei, H. F.M. van der Heijden, E. P. Visser, R. Hermsen, B. A. van Hoorn, J. N.H. Timmer-Bonte, A. T. Willemsen, J. Pruim, F. H.M. Corstens, P. F.M. Krabbe, et al.
Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer
J. Nucl. Med.,
October 1, 2007;
48(10):
1592 - 1598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-M. S. Kong, K. A. Frey, L. E. Quint, R. K. T. Haken, J. A. Hayman, M. Kessler, I. J. Chetty, D. Normolle, A. Eisbruch, and T. S. Lawrence
A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer
J. Clin. Oncol.,
July 20, 2007;
25(21):
3116 - 3123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
Clin. Cancer Res.,
June 15, 2007;
13(12):
3460 - 3469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-K. Teo, Y. Seo, S. L. Bacharach, J. A. Carrasquillo, S. K. Libutti, H. Shukla, B. H. Hasegawa, R. A. Hawkins, and B. L. Franc
Partial-Volume Correction in PET: Validation of an Iterative Postreconstruction Method with Phantom and Patient Data
J. Nucl. Med.,
May 1, 2007;
48(5):
802 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kawada, K. Murakami, T. Sato, Y. Kojima, H. Ebi, H. Mukai, M. Tahara, K. Shimokata, and H. Minami
Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors
Jpn. J. Clin. Oncol.,
January 1, 2007;
37(1):
44 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Biehl, F.-M. Kong, F. Dehdashti, J.-Y. Jin, S. Mutic, I. El Naqa, B. A. Siegel, and J. D. Bradley
18F-FDG PET Definition of Gross Tumor Volume for Radiotherapy of Non-Small Cell Lung Cancer: Is a Single Standardized Uptake Value Threshold Approach Appropriate?
J. Nucl. Med.,
November 1, 2006;
47(11):
1808 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Cachin, H. M. Prince, A. Hogg, R. E. Ware, and R. J. Hicks
Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy
J. Clin. Oncol.,
July 1, 2006;
24(19):
3026 - 3031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Bernstein, S. M. Herbert, and N. H. Hanna
Chemotherapy and Radiotherapy in the Treatment of Resectable Non-Small-Cell Lung Cancer
Ann. Surg. Oncol.,
March 1, 2006;
13(3):
291 - 301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Mawlawi, J. J. Erasmus, R. F. Munden, T. Pan, A. E. Knight, H. A. Macapinlac, D. A. Podoloff, and M. Chasen
Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation
Am. J. Roentgenol.,
February 1, 2006;
186(2):
308 - 319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Kalff, C. Duong, E. G. Drummond, J. P. Matthews, and R. J. Hicks
Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery
J. Nucl. Med.,
January 1, 2006;
47(1):
14 - 22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P J Ell
The contribution of PET/CT to improved patient management
Br. J. Radiol.,
January 1, 2006;
79(937):
32 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al.
Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy
Clin. Cancer Res.,
January 1, 2006;
12(1):
97 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Hoekstra, S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. van Tinteren, P. E. Postmus, R. P. Golding, B. Biesma, F. J.H.M. Schramel, N. van Zandwijk, et al.
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
November 20, 2005;
23(33):
8362 - 8370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol.,
November 1, 2005;
Supplement_28(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
J. Clin. Oncol.,
October 20, 2005;
23(30):
7445 - 7453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med.,
June 1, 2005;
46(6):
983 - 995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Shankar and D. C. Sullivan
Functional Imaging in Lung Cancer
J. Clin. Oncol.,
May 10, 2005;
23(14):
3203 - 3211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res.,
April 15, 2005;
11(8):
2785 - 2808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sasaki, R. Komaki, H. Macapinlac, J. Erasmus, P. Allen, K. Forster, J. B. Putnam, R. S. Herbst, C. A. Moran, D. A. Podoloff, et al.
[18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
February 20, 2005;
23(6):
1136 - 1143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hellwig, T. P. Graeter, D. Ukena, T. Georg, C.-M. Kirsch, and H.-J. Schafers
Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
J. Thorac. Cardiovasc. Surg.,
December 1, 2004;
128(6):
892 - 899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Schwartz, J. Rajendran, B. Yueh, M. D. Coltrera, M. LeBlanc, J. Eary, and K. Krohn
FDG-PET Prediction of Head and Neck Squamous Cell Cancer Outcomes
Arch Otolaryngol Head Neck Surg,
December 1, 2004;
130(12):
1361 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest,
November 1, 2004;
126(5):
1656 - 1666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Schrevens, N. Lorent, C. Dooms, and J. Vansteenkiste
The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer
Oncologist,
November 1, 2004;
9(6):
633 - 643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Thompson and C. B. Thompson
Putting the Rap on Akt
J. Clin. Oncol.,
October 15, 2004;
22(20):
4217 - 4226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Steinke, J. King, D. W. Glenn, and D. L. Morris
Percutaneous Radiofrequency Ablation of Lung Tumors with Expandable Needle Electrodes: Tips from Preliminary Experience
Am. J. Roentgenol.,
September 1, 2004;
183(3):
605 - 611.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Wieder, B. L.D.M. Brucher, F. Zimmermann, K. Becker, F. Lordick, A. Beer, M. Schwaiger, U. Fink, J. R. Siewert, H. J. Stein, et al.
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment
J. Clin. Oncol.,
March 1, 2004;
22(5):
900 - 908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Kamel, D. Zwahlen, M. T. Wyss, K. D. Stumpe, G. K. von Schulthess, and H. C. Steinert
Whole-Body 18F-FDG PET Improves the Management of Patients with Small Cell Lung Cancer
J. Nucl. Med.,
December 1, 2003;
44(12):
1911 - 1917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
